Enhabit, Inc. (NYSE:EHAB - Get Free Report) Director Jeffrey Bolton acquired 4,000 shares of Enhabit stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $8.69 per share, with a total value of $34,760.00. Following the transaction, the director now owns 98,144 shares of the company's stock, valued at $852,871.36. This trade represents a 4.25 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Enhabit Stock Performance
Enhabit stock opened at $8.52 on Friday. Enhabit, Inc. has a fifty-two week low of $6.85 and a fifty-two week high of $11.74. The stock has a fifty day moving average of $7.54 and a two-hundred day moving average of $8.31. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.46 and a quick ratio of 1.46.
Enhabit (NYSE:EHAB - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.01). Enhabit had a positive return on equity of 1.67% and a negative net margin of 11.24%. The company had revenue of $253.60 million for the quarter, compared to analysts' expectations of $261.69 million. During the same quarter in the prior year, the business posted $0.03 EPS. As a group, analysts forecast that Enhabit, Inc. will post 0.22 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
WARNING: “Buffett Indicator” flashing for first time in 50 years
From Behind the Markets | Ad
Warren Buffett has sold a staggering $97 billion worth of stocks this year...
But why?
Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash.
His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Take these 4 steps today to protect your retirement NOW
EHAB has been the subject of several recent analyst reports. Leerink Partners reissued a "market perform" rating and issued a $8.00 price target (down from $8.50) on shares of Enhabit in a report on Tuesday, November 19th. Jefferies Financial Group raised Enhabit from a "hold" rating to a "buy" rating and raised their target price for the company from $8.25 to $9.50 in a report on Monday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $8.75.
Check Out Our Latest Stock Analysis on Enhabit
Institutional Trading of Enhabit
Hedge funds and other institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. boosted its holdings in shares of Enhabit by 19.6% during the third quarter. Franklin Resources Inc. now owns 32,382 shares of the company's stock worth $256,000 after purchasing an additional 5,317 shares during the last quarter. Geode Capital Management LLC lifted its position in Enhabit by 0.9% during the third quarter. Geode Capital Management LLC now owns 1,137,458 shares of the company's stock worth $8,987,000 after buying an additional 10,538 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Enhabit in the 3rd quarter worth about $450,000. XTX Topco Ltd purchased a new stake in Enhabit in the 3rd quarter valued at about $123,000. Finally, Zacks Investment Management acquired a new position in shares of Enhabit during the 3rd quarter valued at about $107,000.
About Enhabit
(
Get Free Report)
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
